ADAMTSL3 knock-out mice develop cardiac dysfunction and dilatation with increased transforming growth factor beta signalling after pressure overload
Karoline B Rypdal 1 2 3, A Olav Melleby 4 5, Emma L Robinson 6, Jia Li 4, Sheryl Palmero 4, Deborah E Seifert 7, Daniel Martin 7, Catelyn Clark 7, Begoña López 8 9, Kristine Andreassen 4, Christen P Dahl 10, Ivar Sjaastad 4, Theis Tønnessen 4 11, Mathis K Stokke 4, William E Louch 4, Arantxa González 8 9, Stephane Heymans 6 12, Geir Christensen 4, Suneel S Apte 7, Ida G Lunde 4 13 14
Heart failure is a major cause of morbidity and mortality worldwide, and can result from pressure overload, where cardiac remodelling is characterized by cardiomyocyte hypertrophy and death, fibrosis, and inflammation. In failing hearts, transforming growth factor (TGF)β drives cardiac fibroblast (CFB) to myofibroblast differentiation causing excessive extracellular matrix production and cardiac remodelling.
New strategies to target pathological TGFβ signalling in heart failure are needed. Here we show that the secreted glycoprotein ADAMTSL3 regulates TGFβ in the heart. We found that Adamtsl3 knock-out mice develop exacerbated cardiac dysfunction and dilatation with increased mortality, and hearts show increased TGFβ activity and CFB activation after pressure overload by aortic banding. Further, ADAMTSL3 overexpression in cultured CFBs inhibits TGFβ signalling, myofibroblast differentiation and collagen synthesis, suggesting a cardioprotective role for ADAMTSL3 by regulating TGFβ activity and CFB phenotype.
These results warrant future investigation of the potential beneficial effects of ADAMTSL3 in heart failure.